"There are three core strengths that separate Third Rock – the experience of its people, the innovation of the science it's pursuing with its portfolio companies and the firm's ability to think big to address some of the most challenging diseases and conditions. Combined, these strengths give Third Rock the capability to help develop new treatments that will have a dramatic and significant impact on patients' lives."
April 4, 2013 - SAGE Therapeutics' Refractory Status Epilepticus Program Demonstrates Efficacy in First-in-Man Experience; Case Study to be Highlighted at International SE Meeting
March 19, 2013 -
Blueprint Medicines Announces First Collaboration with Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center
February 13, 2013 - New Publication in Science Shows That Agios IDH1 Inhibitor Can Reverse Cancer-Causing Effects of Oncometabolite 2HG in Leukemia Model
